Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Kitchin, N., Southern, J., Morris, R., Borrow, R., Fiquet, A., Boisnard, F., Thomas, S., & Miller, E. Vaccine, 27(37):5096–5102, August, 2009.
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine [link]Paper  doi  abstract   bibtex   
This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT5aP-IPV-Hib; Pediacel®) or a whole-cell pertussis (DTwP//Hib + oral poliomyelitis vaccine [OPV]) combination vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) vaccine, followed by a Hib booster at approximately 15 months of age. Immune responses were sustained to 3.5–4.5 years of age for all antigens contained in Pediacel. Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td5ap-IPV; Repevax®), with or without measles, mumps and rubella (M-M-R™II) vaccine, induced robust antibody responses indicative of protection, regardless of the vaccine used for the primary series. Reactogenicity of Repevax was acceptable and consistent with previous experience.
@article{kitchin_antibody_2009,
	title = {Antibody persistence in {UK} pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group {C} conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine},
	volume = {27},
	issn = {0264-410X},
	url = {http://www.sciencedirect.com/science/article/pii/S0264410X09009116},
	doi = {10.1016/j.vaccine.2009.06.049},
	abstract = {This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT5aP-IPV-Hib; Pediacel®) or a whole-cell pertussis (DTwP//Hib + oral poliomyelitis vaccine [OPV]) combination vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) vaccine, followed by a Hib booster at approximately 15 months of age. Immune responses were sustained to 3.5–4.5 years of age for all antigens contained in Pediacel. Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td5ap-IPV; Repevax®), with or without measles, mumps and rubella (M-M-R™II) vaccine, induced robust antibody responses indicative of protection, regardless of the vaccine used for the primary series. Reactogenicity of Repevax was acceptable and consistent with previous experience.},
	number = {37},
	urldate = {2016-06-14},
	journal = {Vaccine},
	author = {Kitchin, Nicholas and Southern, Joanna and Morris, Rhonwen and Borrow, Ray and Fiquet, Anne and Boisnard, Florence and Thomas, Stéphane and Miller, Elizabeth},
	month = aug,
	year = {2009},
	pages = {5096--5102},
}

Downloads: 0